SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:uu-520215"
 

Sökning: id:"swepub:oai:DiVA.org:uu-520215" > Were cancer patient...

  • Johansson, Anna L., VKarolinska Institutet,Canc Registry Norway, POB 5313 Majorstuen, N-0304 Oslo, Norway.;Karolinska Inst, Dept Med Epidemiol & Biostat, POB 281, SE-17177 Stockholm, Sweden. (författare)

Were cancer patients worse off than the general population during the COVID-19 pandemic? : A population-based study from Norway, Denmark and Iceland during the pre-vaccination era

  • Artikel/kapitelEngelska2023

Förlag, utgivningsår, omfång ...

  • Elsevier,2023
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-520215
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-520215URI
  • https://doi.org/10.1016/j.lanepe.2023.100680DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:154350797URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Background In a population-based setting, we investigated the risks of testing positive for SARS-CoV-2 and developing severe COVID-19 outcomes among cancer patients compared with the general population.Methods In nationwide cohorts, we identified all individuals in Norway, Denmark and Iceland who tested positive for SARS-CoV-2 or had a severe COVID-19 outcome (hospitalisation, intensive care, and death) from March until December 2020, using data from national health registries. We estimated standardised incidence ratios (SIRs) with 95% confidence intervals (CIs) comparing cancer patients with the general population.Findings During the first wave of the pandemic, cancer patients in Norway and Denmark had higher risks of testing SARS-CoV-2 positive compared to the general population. Throughout 2020, recently treated cancer patients were more likely to test SARS-CoV-2 positive. In Iceland, cancer patients experienced no increased risk of testing positive. The risk of COVID-19-related hospitalisation was higher among cancer patients diagnosed within one year of hospitalisation (Norway: SIR = 2.43, 95% CI 1.89-3.09; Denmark: 2.23, 1.96-2.54) and within five years (Norway: 1.58, 1.35-1.83; Denmark: 1.54, 1.42-1.66). Risks were higher in recently treated cancer patients and in those diagnosed with haematologic malignancies, colorectal or lung cancer. Risks of COVID-19-related intensive care and death were higher among cancer patients. Interpretation Cancer patients were at increased risk of testing positive for SARS-CoV-2 during the first pandemic wave when testing availability was limited, while relative risks of severe COVID-19 outcomes remained increased in cancer patients throughout 2020. Recent cancer treatment and haematologic malignancy were the strongest risk factors.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Skog, AnnaCanc Registry Norway, POB 5313 Majorstuen, N-0304 Oslo, Norway. (författare)
  • Johannesen, Tom BorgeCanc Registry Norway, POB 5313 Majorstuen, N-0304 Oslo, Norway. (författare)
  • Myklebust, Tor ageCanc Registry Norway, POB 5313 Majorstuen, N-0304 Oslo, Norway.;More & Romsdal Hosp Trust, Dept Res & Innovat, Alesund, Norway. (författare)
  • Skovlund, Charlotte WesselDanish Canc Soc Res Ctr, Danish Canc Soc, Canc Surveillance & Pharmacoepidemiol, Strandboulevarden 49, DK-2100 Copenhagen, Denmark. (författare)
  • Morch, Lina SteinrudDanish Canc Soc Res Ctr, Danish Canc Soc, Canc Surveillance & Pharmacoepidemiol, Strandboulevarden 49, DK-2100 Copenhagen, Denmark. (författare)
  • Friis, SorenDanish Canc Soc Res Ctr, Danish Canc Soc, Canc Surveillance & Pharmacoepidemiol, Strandboulevarden 49, DK-2100 Copenhagen, Denmark. (författare)
  • Gamborg, MadsDanish Canc Soc Res Ctr, Danish Canc Soc, Canc Surveillance & Pharmacoepidemiol, Strandboulevarden 49, DK-2100 Copenhagen, Denmark. (författare)
  • Kristiansen, Marnar FrioheimFac Hlth Sci, Ctr Hlth Sci, Torshavn, Faroe Islands.;Natl Hosp Faroe Isl, Torshavn, Faroe Islands. (författare)
  • Pettersson, DavidNatl Board Hlth & Welf, SE-10630 Stockholm, Sweden. (författare)
  • Olafsdottir, Elinborg J.Iceland Canc Soc, ICS Res & Registrat Ctr, POB 5420, IS-105 Reykjavik, Iceland. (författare)
  • Birgisson, HelgiIceland Canc Soc, ICS Res & Registrat Ctr, POB 5420, IS-105 Reykjavik, Iceland. (författare)
  • Palsson, RunolfurLandspitali The Natl Univ Hosp Iceland, Saemundargata 2, IS-102 Reykjavik, Iceland.;Univ Iceland, Reykjavik, Iceland. (författare)
  • Eythorsson, EliasLandspitali The Natl Univ Hosp Iceland, Saemundargata 2, IS-102 Reykjavik, Iceland. (författare)
  • Irenaeus, SandraUppsala universitet,Cancerimmunterapi,Akadem Sjukhuset, Reg Canc Ctr Cent Sweden, SE-75185 Uppsala, Sweden.(Swepub:uu)sanir765 (författare)
  • Lambe, MatsKarolinska Inst, Dept Med Epidemiol & Biostat, POB 281, SE-17177 Stockholm, Sweden.;Akadem Sjukhuset, Reg Canc Ctr Cent Sweden, SE-75185 Uppsala, Sweden. (författare)
  • Ursin, GiskeCanc Registry Norway, POB 5313 Majorstuen, N-0304 Oslo, Norway.;Univ Oslo, Inst Basic Med Sci, Oslo, Norway.;Univ Southern Calif, Dept Prevent Med, Los Angeles, CA USA. (författare)
  • Karolinska InstitutetCanc Registry Norway, POB 5313 Majorstuen, N-0304 Oslo, Norway.;Karolinska Inst, Dept Med Epidemiol & Biostat, POB 281, SE-17177 Stockholm, Sweden. (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:The Lancet Regional Health: Elsevier312666-7762

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy